Literature DB >> 6272989

Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer.

J A Eisman, L J Suva, E Sher, P J Pearce, J W Funder, T J Martin.   

Abstract

Receptors for 1,25-dihydroxyvitamin D3 have been shown to exist in cultured breast cancer cells and in primary breast cancers. It is reported here that 1,25-dihydroxyvitamin D3 receptor (1,25-DR) was present in 80% of 54 unselected breast cancers. The concentration of 1,25-DR in the 43 receptor-positive tumors was 1.9 +/- 0.4 fmol/mg protein (S.E.). There was no correlation between 1,25-DR presence or concentration and the age of the patient or the concentration of estrogen, progesterone, androgen, or glucocorticoid receptors. 1,25-DR was also found in two of three renal cortical carcinomas but only in three of 14 gastrointestinal tract carcinomas. The relatively low concentration of 1,25-DR in these breast cancers, compared with that found in cultured breast cancer cells, is partially explained by incomplete "exchange" with occupied receptors. Since the serum vitamin D-binding protein is not precipitated from serum itself or from tissue homogenates using the polyethylene glycol method, artifactual 1,25-DR levels due to the inevitable contamination of tissue specimens with this protein can be excluded. These findings indicate that 1,25-DR is not a nonspecific marker of cancer. The high frequency of 1,25-DR in the breast cancers may be related to the calcium-transporting ability of breast cancer cells which allows them to grow as osteolytic metastases.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6272989

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.

Authors:  Jamila Al-Azhri; Yali Zhang; Wiam Bshara; Gary Zirpoli; Susan E McCann; Thaer Khoury; Carl D Morrison; Stephen B Edge; Christine B Ambrosone; Song Yao
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

Review 2.  The role of vitamin D in pregnancy and lactation: emerging concepts.

Authors:  Carol L Wagner; Sarah N Taylor; Donna D Johnson; Bruce W Hollis
Journal:  Womens Health (Lond)       Date:  2012-05

3.  1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.

Authors:  Y Iino; M Yoshida; N Sugamata; M Maemura; S Ohwada; T Yokoe; T Ishikita; R Horiuchi; Y Morishita
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Combined effects of 1,25-dihydroxyvitamin D3 and tamoxifen on the growth of MCF-7 and ZR-75-1 human breast cancer cells.

Authors:  T Vink-van Wijngaarden; H A Pols; C J Buurman; J C Birkenhäger; J P van Leeuwen
Journal:  Breast Cancer Res Treat       Date:  1994-02       Impact factor: 4.872

Review 5.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

Review 6.  Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus.

Authors:  Carol L Wagner; Sarah N Taylor; Adekunle Dawodu; Donna D Johnson; Bruce W Hollis
Journal:  Nutrients       Date:  2012-03-21       Impact factor: 5.717

7.  Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.

Authors:  Timothy M Pawlik; David H Hawke; Yanna Liu; Savitri Krishnamurthy; Herbert Fritsche; Kelly K Hunt; Henry M Kuerer
Journal:  BMC Cancer       Date:  2006-03-16       Impact factor: 4.430

8.  Assessment of functional variants and expression of long noncoding RNAs in vitamin D receptor signaling in breast cancer.

Authors:  Vahid Kholghi Oskooei; Lobat Geranpayeh; Mir Davood Omrani; Soudeh Ghafouri-Fard
Journal:  Cancer Manag Res       Date:  2018-09-12       Impact factor: 3.989

9.  Calcitriol and cancer therapy: A missed opportunity.

Authors:  Donald L Trump
Journal:  Bone Rep       Date:  2018-06-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.